( Australia:ANP, OTC-PINK:ATHJY )

News from Antisense Therapeutics Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

22 Sep, 2014, 09:00 ET ATL1102 for MS - Phase II trial results published in the leading Medical Journal Neurology

Antisense Therapeutics (the "Company" or "ANP") is pleased to report the publication of previously generated Phase IIa clinical trial data on...


02 Sep, 2014, 19:19 ET ATL1103 Phase II Trial - Successful Efficacy Results

Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to report the primary efficacy results from its Phase II clinical trial of...


29 Jul, 2014, 08:00 ET ATL1103 Acromegaly Phase II Trial Dosing Completed

Antisense Therapeutics Limited ("ANP") is pleased to report that dosing of all 26 patients in the Phase II trial of ATL1103 for the potentially...


01 Apr, 2014, 09:45 ET ATL1102 for MS - Toxicology Study Main Findings

Antisense Therapeutics Limited ("ANP" or the "Company") is pleased to advise that results from a chronic toxicity study in monkeys indicate that...


07 Jan, 2014, 17:49 ET Antisense Therapeutics Selected to Present at Biotech Showcase™ 2014

 Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to advise that it has been selected to present at the Biotech Showcase 2014...


23 Dec, 2013, 07:15 ET Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial

 Antisense Therapeutics Limited ("ANP" or "the Company") is pleased to advise that positive results have been achieved from the interim...


28 Aug, 2013, 07:30 ET ANP to present at and attend major US investment, partnering and industry conferences

 Antisense Therapeutics Limited (ASX:ANP) is pleased to advise that its Chief Executive Officer and Managing Director, Mark Diamond has been...


13 Jan, 2005, 00:00 ET Antisense Therapeutics Announces Launch of Level 1 American Depository Receipt Program

MELBOURNE, Australia, Jan. 13 /PRNewswire-FirstCall/ -- Antisense Therapeutics Limited (ASX: ANP) today announced that its Level One American...


22 Apr, 2004, 01:00 ET Antisense Therapeutics CEO Mark Diamond Interviewed by Wall Street Reporter

VICTORIA, Australia, April 22 /PRNewswire/ -- Antisense Therapeutics Limited (ASX: ANP), a biopharmaceutical company, announced that CEO Mark...


02 Feb, 2004, 00:00 ET Antisense Therapeutics Presents Preliminary ATL1102 Phase I Results At Neurosciences Conference

VICTORIA, Australia, Feb. 2 /PRNewswire/ -- Antisense Therapeutics Limited (ASX: ANP), a biopharmaceutical company today announced that...


13 Jan, 2004, 00:00 ET Antisense Therapeutics CEO Mark Diamond to be Featured Guest on Biotech Today Radio Program

VICTORIA, Australia, Jan. 13 /PRNewswire/ -- Antisense Therapeutics Limited (ASX: ANP), a biopharmaceutical company today announced that CEO...